Botiacrine (INNTooltip International Nonproprietary Name; developmental code name Mo 876) is a drug of the tricyclic family described as an antiparkinsonian agent which was either never marketed or was possibly marketed outside of the United States.

[1][2][3][4][5] It was first described in the literature by 1965.

[1] The drug is an acridine derivative and is structurally related to the tricyclic antidepressant dimetacrine.

This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.